Virtual Meeting to be held on April 22-23 hosted by B. Riley.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

B.Riley has initiated coverage on shares of Nektar Therapeutics with a Buy rating, based on the potential of REZPEG, which is currently in Phase IIb trials for atopic dermatitis and alopecia areata.

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. "The significant progress we made ...

Nektar's market capitalization is currently around $93 million. The firm also pointed to Nektar's cash position of $269.1 million at the end of 2024, which is expected to fund operations through ...

Fintel reports that on April 11, 2025, Jefferies upgraded their outlook for Nektar Therapeutics (LSE:0UNL) from Hold to Buy. As of January 29, 2025, the average one-year price target for Nektar ...